Administration of the adenosine receptor 2a (A2A) agonist in lupus mice depletes CD11c+T-bet+ B-cell proliferation, inhibits ANA production in serum, and alleviates kidney pathology and lymphadenopathy (35). The gene discussed is ITGAX; the disease is systemic lupus erythematosus.